ENXTPA:GBT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide.


Snowflake Analysis

Adequate balance sheet average dividend payer.


Similar Companies

Share Price & News

How has Guerbet's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GBT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

2.7%

GBT

-11.5%

FR Medical Equipment

8.7%

FR Market


1 Year Return

-25.6%

GBT

42.8%

FR Medical Equipment

-2.4%

FR Market

Return vs Industry: GBT underperformed the French Medical Equipment industry which returned 47.4% over the past year.

Return vs Market: GBT underperformed the French Market which returned -3.8% over the past year.


Shareholder returns

GBTIndustryMarket
7 Day2.7%-11.5%8.7%
30 Day24.9%-1.9%15.9%
90 Day16.2%35.6%1.3%
1 Year-25.6%-25.6%42.8%42.8%-0.7%-2.4%
3 Year-55.4%-56.8%43.9%42.1%11.2%2.2%
5 Year-5.1%-10.0%144.9%139.2%31.1%14.3%

Price Volatility Vs. Market

How volatile is Guerbet's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Guerbet undervalued compared to its fair value and its price relative to the market?

12.11x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: GBT (€35.9) is trading above our estimate of fair value (€20.97)

Significantly Below Fair Value: GBT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GBT is good value based on its PE Ratio (12.1x) compared to the Medical Equipment industry average (47.3x).

PE vs Market: GBT is good value based on its PE Ratio (12.1x) compared to the French market (15.1x).


Price to Earnings Growth Ratio

PEG Ratio: GBT is poor value based on its PEG Ratio (11.7x)


Price to Book Ratio

PB vs Industry: GBT is good value based on its PB Ratio (1.2x) compared to the FR Medical Equipment industry average (2.6x).


Next Steps

Future Growth

How is Guerbet forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

1.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GBT's forecast earnings growth (1% per year) is above the savings rate (0.6%).

Earnings vs Market: GBT's earnings (1% per year) are forecast to grow slower than the French market (13.6% per year).

High Growth Earnings: GBT's earnings are forecast to grow, but not significantly.

Revenue vs Market: GBT's revenue is expected to decline over the next 3 years (-0.1% per year).

High Growth Revenue: GBT's revenue is forecast to decline over the next 3 years (-0.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GBT's Return on Equity is forecast to be low in 3 years time (9.3%).


Next Steps

Past Performance

How has Guerbet performed over the past 5 years?

7.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GBT has high quality earnings.

Growing Profit Margin: GBT's current net profit margins (4.6%) are lower than last year (5.9%).


Past Earnings Growth Analysis

Earnings Trend: GBT's earnings have grown by 7.9% per year over the past 5 years.

Accelerating Growth: GBT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GBT had negative earnings growth (-20.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (-1.8%).


Return on Equity

High ROE: GBT's Return on Equity (9.6%) is considered low.


Next Steps

Financial Health

How is Guerbet's financial position?


Financial Position Analysis

Short Term Liabilities: GBT's short term assets (€515.2M) exceed its short term liabilities (€215.9M).

Long Term Liabilities: GBT's short term assets (€515.2M) exceed its long term liabilities (€403.7M).


Debt to Equity History and Analysis

Debt Level: GBT's debt to equity ratio (93%) is considered high.

Reducing Debt: GBT's debt to equity ratio has increased from 30% to 93% over the past 5 years.

Debt Coverage: GBT's debt is well covered by operating cash flow (36.3%).

Interest Coverage: GBT's interest payments on its debt are well covered by EBIT (7x coverage).


Balance Sheet


Next Steps

Dividend

What is Guerbet's current dividend yield, its reliability and sustainability?

1.95%

Current Dividend Yield


Upcoming Dividend Payment


Dividend Yield vs Market

Notable Dividend: GBT's dividend (1.95%) is higher than the bottom 25% of dividend payers in the French market (1.65%).

High Dividend: GBT's dividend (1.95%) is low compared to the top 25% of dividend payers in the French market (4.82%).


Stability and Growth of Payments

Stable Dividend: GBT's dividend payments have been volatile in the past 10 years.

Growing Dividend: GBT's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (23.6%), GBT's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: GBT's dividends in 3 years are forecast to be well covered by earnings (23.1% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

David Hale (50yo)

0.42

Tenure

Mr. David Hale has been Chief Executive Officer of Guerbet SA since January 1, 2020. Mr. Hale served as Chief Commercial Officer of Guerbet SA since 2019 until January 1, 2020 and served as its Chief Comme ...


Leadership Team

NamePositionTenureCompensationOwnership
Pierre André
Chief Pharmaceutical Officer & Deputy CEO4.17yrs€236.95kno data
David Hale
Chief Executive Officer0.42yrno datano data
Jérôme Estampes
Chief Financial Officer1.17yrsno datano data
Elena Puntorieri
Vice President of Purchasing & Member of Management Boardno datano datano data
Anne-Laure Delasalle
Vice President of Communications & Imageno datano datano data
Antoine Mazraani
VP of European Operations & Member of Management Boardno datano datano data
Alain Le Jeune
Member of Management Boardno datano datano data
Frédéric Duchet
Chief Information Officer & Member of Management Boardno datano datano data
Petra Zalabak
Vice President of Human Resources0.42yrno datano data
François Nicolas
Chief Digital Officer and VP of Contrast Injection Systems R&D2.75yrsno datano data

1.2yrs

Average Tenure

50yo

Average Age

Experienced Management: GBT's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Marion Barbier
Non-Independent Director8.92yrs€24.00kno data
Thibault Viort
Independent Director3.08yrs€25.50kno data
Michel Guerbet
Honorary Chairmanno data€18.96k54.87% 247.3m
Marie-Claire Janailhac-Fritsch
Independent Chairwoman of the Board6.75yrs€124.13kno data
Claire Jouault-Massiot
Non-Independent Director7.08yrs€27.00kno data
Mark Fouquet
Non-Independent Director6.08yrs€26.00kno data
Didier Izabel
Independent Director6.08yrs€37.50kno data
Céline Lamort
Non-Independent Director5.08yrs€23.00kno data
Nicolas Louvet
Non-Independent Director4.08yrs€24.00kno data
Eric Guerbet
Non-Independent Director3.08yrs€22.50kno data

6.1yrs

Average Tenure

58yo

Average Age

Experienced Board: GBT's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Guerbet SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Guerbet SA
  • Ticker: GBT
  • Exchange: ENXTPA
  • Founded: 1926
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: €450.633m
  • Shares outstanding: 12.55m
  • Website: https://www.guerbet.com

Number of Employees


Location

  • Guerbet SA
  • 15, rue des Vanesses
  • Zone Paris Nord II
  • Villepinte
  • Ile-de-France
  • 93420
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GUER.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJan 1992
GBTENXTPA (Euronext Paris)YesOrdinary SharesFREURJan 1992
0ELVLSE (London Stock Exchange)YesOrdinary SharesGBEURJan 1992
4G8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 1992
GBTPBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJan 1992
GBTNVENXTPA (Euronext Paris)EUR1 (RFD 01/01/2020)FREURJan 2020

Biography

Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide. Its products for the CT and Cath Lab examinations include Optiray, a low osmolar contrast medium; Xenetix, a low-osmolar iodinated agent; Telebrix, a high osmolar contrast medium; Conray and MD high osmolar contrast medium products; and high osmolar contrast medium, an ionic low osmolar contrast medium agent. The company’s products for the magnetic resonance imaging (MRI) examinations comprise Dotarem, a non-specific gadolinium-based contrast medium; Artirem products; and Optimark, a contrast medium. In addition, it provides products for interventional imaging, including Lipiodol ethyl esters of iodinated fatty acids of poppy seed oil; Vectorio, a classic transarterial chemoembolization mixing and injection system; and Patent Blue V, an injectable medium. Further, the company offers delivery systems and services comprising injectors; consumables for various types of injectors; and Contrast&Care, a patient data management software. The company distributes its products directly, as well as through distributors and license-holders primarily to hospitals, clinics, radiology centers, purchasing pools, and wholesalers. Guerbet SA was founded in 1926 and is headquartered in Villepinte, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 20:47
End of Day Share Price2020/06/05 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.